Serum TIMP-1 Predicts Survival Outcomes of Invasive Breast Carcinoma Patients

A Meta-analysis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background and Aims: Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a small secretory glycoprotein with multifunctional activity including anti-apoptosis and the inhibition of matrix metalloproteinase in invasive breast carcinomas. There have been contradictory results as to whether TIMP-1 is a poor or good prognostic factor in breast cancer patients. To address this controversy, we conducted a meta-analysis for the relationship between TIMP-1 levels and prognostic parameters in the breast cancer. Methods: The relevant published studies were pooled according to the defined selection criteria. The effect sizes of overall survival and prognostic parameters were calculated by a hazard ratio (HR) or an odds ratio (OR). HRs or ORs were combined using a random-effects model. Results: Survival outcomes between high or elevated and low or normal serum TIMP-1 levels were compared by uni- and multivariate analyses involving 886 and 844 breast cancer patients, respectively. Patients with high or elevated serum TIMP-1 levels had unfavorable survival outcomes compared to patients with low or normal serum TIMP-1 levels in the uni- and multivariate analyses (HR, 1.7 and 2.4; p <0.001 and p = 0.033, respectively). However, no survival difference was evident in the data from tissue TIMP-1 levels by enzyme-linked immunosorbent assay and the expression of tissue TIMP-1 mRNA. The high or positive immunohistochemical expression of tissue TIMP-1 protein was not related to adjusted and unadjusted HRs, lymph node metastasis, and clinical stages. Conclusions: This meta-analysis indicates that serum TIMP-1 levels may be useful for predicting survival outcomes of invasive breast cancer patients.

Original languageEnglish
Pages (from-to)463-468
Number of pages6
JournalArchives of Medical Research
Volume42
Issue number6
DOIs
Publication statusPublished - 2011 Aug 1

Fingerprint

Tissue Inhibitor of Metalloproteinase-1
Meta-Analysis
Breast Neoplasms
Survival
Serum
Multivariate Analysis
Matrix Metalloproteinases
Patient Selection
Glycoproteins
Lymph Nodes
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Apoptosis
Neoplasm Metastasis
Messenger RNA

Keywords

  • Breast cancer
  • Meta-analysis
  • Survival
  • TIMP-1

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{537ec4233f674ec59493417fb3e0edd2,
title = "Serum TIMP-1 Predicts Survival Outcomes of Invasive Breast Carcinoma Patients: A Meta-analysis",
abstract = "Background and Aims: Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a small secretory glycoprotein with multifunctional activity including anti-apoptosis and the inhibition of matrix metalloproteinase in invasive breast carcinomas. There have been contradictory results as to whether TIMP-1 is a poor or good prognostic factor in breast cancer patients. To address this controversy, we conducted a meta-analysis for the relationship between TIMP-1 levels and prognostic parameters in the breast cancer. Methods: The relevant published studies were pooled according to the defined selection criteria. The effect sizes of overall survival and prognostic parameters were calculated by a hazard ratio (HR) or an odds ratio (OR). HRs or ORs were combined using a random-effects model. Results: Survival outcomes between high or elevated and low or normal serum TIMP-1 levels were compared by uni- and multivariate analyses involving 886 and 844 breast cancer patients, respectively. Patients with high or elevated serum TIMP-1 levels had unfavorable survival outcomes compared to patients with low or normal serum TIMP-1 levels in the uni- and multivariate analyses (HR, 1.7 and 2.4; p <0.001 and p = 0.033, respectively). However, no survival difference was evident in the data from tissue TIMP-1 levels by enzyme-linked immunosorbent assay and the expression of tissue TIMP-1 mRNA. The high or positive immunohistochemical expression of tissue TIMP-1 protein was not related to adjusted and unadjusted HRs, lymph node metastasis, and clinical stages. Conclusions: This meta-analysis indicates that serum TIMP-1 levels may be useful for predicting survival outcomes of invasive breast cancer patients.",
keywords = "Breast cancer, Meta-analysis, Survival, TIMP-1",
author = "Ju-Han Lee and Jung-Woo Choi and Kim, {Young Sik}",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.arcmed.2011.09.006",
language = "English",
volume = "42",
pages = "463--468",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Serum TIMP-1 Predicts Survival Outcomes of Invasive Breast Carcinoma Patients

T2 - A Meta-analysis

AU - Lee, Ju-Han

AU - Choi, Jung-Woo

AU - Kim, Young Sik

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Background and Aims: Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a small secretory glycoprotein with multifunctional activity including anti-apoptosis and the inhibition of matrix metalloproteinase in invasive breast carcinomas. There have been contradictory results as to whether TIMP-1 is a poor or good prognostic factor in breast cancer patients. To address this controversy, we conducted a meta-analysis for the relationship between TIMP-1 levels and prognostic parameters in the breast cancer. Methods: The relevant published studies were pooled according to the defined selection criteria. The effect sizes of overall survival and prognostic parameters were calculated by a hazard ratio (HR) or an odds ratio (OR). HRs or ORs were combined using a random-effects model. Results: Survival outcomes between high or elevated and low or normal serum TIMP-1 levels were compared by uni- and multivariate analyses involving 886 and 844 breast cancer patients, respectively. Patients with high or elevated serum TIMP-1 levels had unfavorable survival outcomes compared to patients with low or normal serum TIMP-1 levels in the uni- and multivariate analyses (HR, 1.7 and 2.4; p <0.001 and p = 0.033, respectively). However, no survival difference was evident in the data from tissue TIMP-1 levels by enzyme-linked immunosorbent assay and the expression of tissue TIMP-1 mRNA. The high or positive immunohistochemical expression of tissue TIMP-1 protein was not related to adjusted and unadjusted HRs, lymph node metastasis, and clinical stages. Conclusions: This meta-analysis indicates that serum TIMP-1 levels may be useful for predicting survival outcomes of invasive breast cancer patients.

AB - Background and Aims: Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a small secretory glycoprotein with multifunctional activity including anti-apoptosis and the inhibition of matrix metalloproteinase in invasive breast carcinomas. There have been contradictory results as to whether TIMP-1 is a poor or good prognostic factor in breast cancer patients. To address this controversy, we conducted a meta-analysis for the relationship between TIMP-1 levels and prognostic parameters in the breast cancer. Methods: The relevant published studies were pooled according to the defined selection criteria. The effect sizes of overall survival and prognostic parameters were calculated by a hazard ratio (HR) or an odds ratio (OR). HRs or ORs were combined using a random-effects model. Results: Survival outcomes between high or elevated and low or normal serum TIMP-1 levels were compared by uni- and multivariate analyses involving 886 and 844 breast cancer patients, respectively. Patients with high or elevated serum TIMP-1 levels had unfavorable survival outcomes compared to patients with low or normal serum TIMP-1 levels in the uni- and multivariate analyses (HR, 1.7 and 2.4; p <0.001 and p = 0.033, respectively). However, no survival difference was evident in the data from tissue TIMP-1 levels by enzyme-linked immunosorbent assay and the expression of tissue TIMP-1 mRNA. The high or positive immunohistochemical expression of tissue TIMP-1 protein was not related to adjusted and unadjusted HRs, lymph node metastasis, and clinical stages. Conclusions: This meta-analysis indicates that serum TIMP-1 levels may be useful for predicting survival outcomes of invasive breast cancer patients.

KW - Breast cancer

KW - Meta-analysis

KW - Survival

KW - TIMP-1

UR - http://www.scopus.com/inward/record.url?scp=82855182179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82855182179&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2011.09.006

DO - 10.1016/j.arcmed.2011.09.006

M3 - Article

VL - 42

SP - 463

EP - 468

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 6

ER -